Universität zu Köln

Hampel, Harald, Lista, Simone ORCID: 0000-0001-6804-7858, Teipel, Stefan J., Garaci, Francesco, Nistico, Robert ORCID: 0000-0003-3433-9232, Blennow, Kaj, Zetterberg, Henrik, Bertram, Lars ORCID: 0000-0002-0108-124X, Duyckaerts, Charles, Bakardjian, Hovagim, Drzezga, Alexander, Colliot, Olivier, Epelbaum, Stephane ORCID: 0000-0003-4059-2891, Broich, Karl, Lehericy, Stephane, Brice, Alexis, Khachaturian, Zaven S., Aisen, Paul S. and Dubois, Bruno (2014). Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: A long-range point of view beyond 2020. Biochem. Pharmacol., 88 (4). S. 426 - 450. OXFORD: PERGAMON-ELSEVIER SCIENCE LTD. ISSN 1873-2968

Full text not available from this repository.

Abstract

Recent advances in understanding the molecular mechanisms underlying various paths toward the pathogenesis of Alzheimer's disease (AD) has begun to provide new insight for interventions to modify disease progression. The evolving knowledge gained from multidisciplinary basic research has begun to identify new concepts for treatments and distinct classes of therapeutic targets; as well as putative disease-modifying compounds that are now being tested in clinical trials. There is a mounting consensus that such disease modifying compounds and/or interventions are more likely to be effectively administered as early as possible in the cascade of pathogenic processes preceding and underlying the clinical expression of AD. The budding sentiment is that treatments need to be applied before various molecular mechanisms converge into an irreversible pathway leading to morphological, metabolic and functional alterations that characterize the pathophysiology of AD. In light of this, biological indicators of pathophysiological mechanisms are desired to chart and detect AD throughout the asymptomatic early molecular stages into the prodromal and early dementia phase. A major conceptual development in the clinical AD research field was the recent proposal of new diagnostic criteria, which specifically incorporate the use of biomarkers as defining criteria for preclinical stages of AD. This paradigm shift in AD definition, conceptualization, operationalization, detection and diagnosis represents novel fundamental opportunities for the modification of interventional trial designs. This perspective summarizes not only present knowledge regarding biological markers but also unresolved questions on the status of surrogate indicators for detection of the disease in asymptomatic people and diagnosis of AD. (C) 2013 Elsevier Inc. All rights reserved.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Hampel, Harald UNSPECIFIED UNSPECIFIED UNSPECIFIED Lista, Simone UNSPECIFIED orcid.org/0000-0001-6804-7858 UNSPECIFIED Teipel, Stefan J. UNSPECIFIED UNSPECIFIED UNSPECIFIED Garaci, Francesco UNSPECIFIED UNSPECIFIED UNSPECIFIED Nistico, Robert UNSPECIFIED orcid.org/0000-0003-3433-9232 UNSPECIFIED Blennow, Kaj UNSPECIFIED UNSPECIFIED UNSPECIFIED Zetterberg, Henrik UNSPECIFIED UNSPECIFIED UNSPECIFIED Bertram, Lars UNSPECIFIED orcid.org/0000-0002-0108-124X UNSPECIFIED Duyckaerts, Charles UNSPECIFIED UNSPECIFIED UNSPECIFIED Bakardjian, Hovagim UNSPECIFIED UNSPECIFIED UNSPECIFIED Drzezga, Alexander UNSPECIFIED UNSPECIFIED UNSPECIFIED Colliot, Olivier UNSPECIFIED UNSPECIFIED UNSPECIFIED Epelbaum, Stephane UNSPECIFIED orcid.org/0000-0003-4059-2891 UNSPECIFIED Broich, Karl UNSPECIFIED UNSPECIFIED UNSPECIFIED Lehericy, Stephane UNSPECIFIED UNSPECIFIED UNSPECIFIED Brice, Alexis UNSPECIFIED UNSPECIFIED UNSPECIFIED Khachaturian, Zaven S. UNSPECIFIED UNSPECIFIED UNSPECIFIED Aisen, Paul S. UNSPECIFIED UNSPECIFIED UNSPECIFIED Dubois, Bruno UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-440672
DOI:	10.1016/j.bcp.2013.11.009
Journal or Publication Title:	Biochem. Pharmacol.
Volume:	88
Number:	4
Page Range:	S. 426 - 450
Date:	2014
Publisher:	PERGAMON-ELSEVIER SCIENCE LTD
Place of Publication:	OXFORD
ISSN:	1873-2968
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language MILD COGNITIVE IMPAIRMENT; CEREBROSPINAL-FLUID BIOMARKERS; DIFFUSION-TENSOR MRI; POSITRON-EMISSION-TOMOGRAPHY; MAGNETIC-RESONANCE IMAGES; BETA-AMYLOID PEPTIDE(42); EVENT-RELATED POTENTIALS; PLASMA-PROTEOME-PROJECT; GENOME-WIDE ASSOCIATION; TRANSGENIC MOUSE MODEL Multiple languages Pharmacology & Pharmacy Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/44067